Total Payments
$3,402
2024 Payments
$1,038
Companies
39
Transactions
166
Medicare Patients
2,380
Medicare Billing
$240,854
Payment Breakdown by Category
Food & Beverage$3,033 (89.2%)
Education$368.06 (10.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,033 | 149 | 89.2% |
| Education | $368.06 | 17 | 10.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $322.25 | 25 | $0 (2024) |
| Exelixis Inc. | $269.41 | 8 | $0 (2023) |
| Seagen Inc. | $218.70 | 11 | $0 (2023) |
| Genentech USA, Inc. | $184.43 | 10 | $0 (2023) |
| Eisai Inc. | $165.22 | 7 | $0 (2024) |
| Astellas Pharma US Inc | $161.03 | 7 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $150.28 | 5 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $133.56 | 7 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $129.19 | 6 | $0 (2024) |
| Celgene Corporation | $122.04 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,038 | 44 | Takeda Pharmaceuticals U.S.A., Inc. ($111.22) |
| 2023 | $910.00 | 43 | Seagen Inc. ($140.26) |
| 2022 | $251.40 | 11 | Exelixis Inc. ($82.40) |
| 2021 | $454.99 | 26 | PFIZER INC. ($123.46) |
| 2020 | $224.40 | 11 | Exelixis Inc. ($65.92) |
| 2019 | $226.64 | 13 | Genentech USA, Inc. ($78.91) |
| 2018 | $87.47 | 5 | Eisai Inc. ($22.69) |
| 2017 | $208.17 | 13 | AstraZeneca Pharmaceuticals LP ($30.74) |
All Payment Transactions
166 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $25.86 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $19.56 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $23.66 | General |
| Category: Hematology/Oncology | ||||||
| 11/15/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $34.02 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $18.72 | General |
| Category: ONCOLOGY | ||||||
| 10/15/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $25.44 | General |
| Category: Oncology | ||||||
| 10/10/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $19.09 | General |
| Category: ONCOLOGY | ||||||
| 10/01/2024 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 09/03/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $28.93 | General |
| Category: ONCOLOGY | ||||||
| 08/27/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: Oncology | ||||||
| 08/13/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $28.03 | General |
| Category: ONCOLOGY | ||||||
| 07/16/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $28.67 | General |
| Category: Oncology | ||||||
| 07/10/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $23.18 | General |
| 06/25/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $19.94 | General |
| Category: Oncology | ||||||
| 06/18/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $19.64 | General |
| Category: ONCOLOGY | ||||||
| 06/12/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $24.99 | General |
| Category: Oncology | ||||||
| 06/04/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $29.64 | General |
| Category: ONCOLOGY | ||||||
| 05/29/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $30.92 | General |
| Category: Oncology | ||||||
| 05/21/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $33.16 | General |
| Category: Hematology | ||||||
| 05/21/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $21.70 | General |
| Category: Oncology | ||||||
| 05/17/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $22.44 | General |
| Category: Oncology | ||||||
| 05/16/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $22.43 | General |
| Category: ONCOLOGY | ||||||
| 05/15/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $32.92 | General |
| Category: Oncology | ||||||
| 05/14/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $27.96 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 585 | 837 | $269,189 | $58,952 |
| 2022 | 7 | 596 | 872 | $276,847 | $63,866 |
| 2021 | 7 | 625 | 845 | $274,958 | $63,688 |
| 2020 | 8 | 574 | 824 | $277,285 | $54,348 |
Total Patients
2,380
Total Services
3,378
Medicare Billing
$240,854
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 255 | 428 | $134,392 | $28,233 | 21.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 144 | 197 | $61,858 | $14,010 | 22.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 38 | 38 | $18,392 | $3,665 | 19.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 19 | 24 | $10,128 | $2,698 | 26.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 18 | 18 | $10,818 | $2,559 | 23.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 21 | 38 | $7,980 | $2,363 | 29.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 52 | 54 | $11,502 | $2,323 | 20.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 12 | 14 | $5,600 | $1,433 | 25.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $5,324 | $942.48 | 17.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 15 | 15 | $3,195 | $725.48 | 22.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 244 | 415 | $130,310 | $30,274 | 23.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 150 | 221 | $69,394 | $15,890 | 22.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 20 | 23 | $13,524 | $3,577 | 26.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 66 | 75 | $15,975 | $3,201 | 20.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 32 | 32 | $15,488 | $3,049 | 19.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 18 | 18 | $10,818 | $2,638 | 24.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 21 | 41 | $8,610 | $2,292 | 26.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 11 | 13 | $5,486 | $1,503 | 27.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 34 | 34 | $7,242 | $1,442 | 19.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 233 | 360 | $113,040 | $25,674 | 22.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 167 | 229 | $71,906 | $16,548 | 23.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 24 | 28 | $16,464 | $4,463 | 27.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 30 | 30 | $18,030 | $4,253 | 23.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 32 | 32 | $15,488 | $3,141 | 20.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 52 | 57 | $12,141 | $2,699 | 22.2% |
About Dr. Kelly May, MD
Dr. Kelly May, MD is a Hematology & Oncology healthcare provider based in Atlanta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/20/2007. The National Provider Identifier (NPI) number assigned to this provider is 1548444045.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kelly May, MD has received a total of $3,402 in payments from pharmaceutical and medical device companies, with $1,038 received in 2024. These payments were reported across 166 transactions from 39 companies. The most common payment nature is "Food and Beverage" ($3,033).
As a Medicare-enrolled provider, May has provided services to 2,380 Medicare beneficiaries, totaling 3,378 services with total Medicare billing of $240,854. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Atlanta, GA
- Active Since 12/20/2007
- Last Updated 08/27/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1548444045
Products in Payments
- IBRANCE (Drug) $198.31
- Lenvima (Drug) $165.22
- Padcev (Drug) $127.36
- TUKYSA (Drug) $124.97
- SOMATULINE DEPOT (Drug) $120.39
- REBLOZYL (Biological) $100.32
- Cabometyx (Drug) $100.06
- BRUKINSA (Drug) $84.28
- Perjeta (Biological) $80.55
- VERZENIO (Drug) $77.55
- Nubeqa (Drug) $75.47
- ADCETRIS (Biological) $72.90
- Enhertu (Drug) $72.71
- OJJAARA (Drug) $70.50
- OXBRYTA (Drug) $67.86
- ELREXFIO (Drug) $66.13
- DARZALEX (Biological) $63.17
- KEYTRUDA (Biological) $63.05
- ALUNBRIG (Drug) $62.05
- ENHERTU (Biological) $58.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Atlanta
Dr. Jonathon Cohen, M.d, M.D
Hematology & Oncology — Payments: $330,523
Hematology & Oncology $330,523
Dr. Ajay Nooka, M.d., M.p.h.,F.a.c.p, M.D., M.P.H.,F.A.C.P
Hematology & Oncology — Payments: $256,358
Hematology & Oncology $256,358
Dr. Rodolfo Bordoni, Md, MD
Hematology & Oncology — Payments: $240,507
Hematology & Oncology $240,507
Dr. Mehmet Bilen, M.d, M.D
Hematology & Oncology — Payments: $134,196
Hematology & Oncology $134,196
Olatunji Alese, M.d, M.D
Hematology & Oncology — Payments: $131,083
Hematology & Oncology $131,083
Dr. Carlos Franco, Md, MD
Hematology & Oncology — Payments: $115,439
Hematology & Oncology $115,439